This is the authors' abstract. We don't add key points for this paper.
An international group of 22 liver cancer experts from 18 institutions met in Miami, Florida to discuss the optimal utilization of proton beam therapy (PBT) for primary and metastatic liver cancer. There was consensus that PBT may be preferred for liver cancer patients expected to have a suboptimal therapeutic ratio from XRT, but that PBT should not be preferred for all patients. Various clinical scenarios demonstrating appropriateness of PBT vs. XRT were reviewed.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chuong et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: